Predicta Biosciences builds laboratory-developed tests that combine deep genomic and immune profiling to improve the diagnosis and management of blood cancers such as multiple myeloma. Its first product, GenoPredicta, launched in April and can be run on either peripheral blood or bone marrow to help physicians identify molecular drivers of disease and predict patient response to immunotherapies like CAR-T cells and bispecific antibodies. The company operates a CLIA-approved laboratory and plans to use new capital to expand both its team and lab infrastructure. Beyond diagnostics, Predicta intends to leverage its growing dataset to discover and commercialize precision therapeutics. The firm collaborates with clinical providers and advocacy groups, including the HealthTree Foundation, to accelerate adoption. Brian McKernan, a three-time biotech founder and former CEO of Fluent BioSciences, has been appointed CEO to steer commercialization and future product development. Financial metrics such as revenue or user numbers were not disclosed in the article.

Total raised

$29M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2025